Time to Clearance of Neisseria gonorrhoeae RNA at the Pharynx following Treatment.
NAAT
Neisseria gonorrhoeae
clearance
Journal
Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564
Informations de publication
Date de publication:
15 06 2022
15 06 2022
Historique:
pubmed:
6
5
2022
medline:
18
6
2022
entrez:
5
5
2022
Statut:
ppublish
Résumé
The number of days until pharyngeal Neisseria gonorrhoeae nucleic acid amplification test (NAAT) results become negative after treatment remains unknown. Between March 2019 and April 2021, we enrolled men who have sex with men (MSM) who had a clinical positive pharyngeal N. gonorrhoeae Aptima Combo 2 test result but had not yet been treated in a prospective longitudinal cohort study. MSM were enrolled on their day of treatment and self-collected daily pharyngeal specimens for 21 days at home. We used Kaplan-Meier estimates to determine the median time to clearance and the >95% time to clearance and the log rank test for equality to evaluate factors associated with time to clearance. Sixty-four men were enrolled in the study. Analyses excluded 8 men (12.5%) who were N. gonorrhoeae negative by NAAT at enrollment and 11 (17%) who failed to return any home-collected specimens. Among the 45 men included in the analysis, the median time to N. gonorrhoeae NAAT clearance was 3 days (95% confidence interval [CI], 2 to 5 days). Time to clearance for >95% of the cohort was 12 days (95% CI, 10 days to an undefined time). Men with a history of N. gonorrhoeae infection cleared faster than men without such history (8 days versus 17 days for >95% time to clearance;
Identifiants
pubmed: 35510509
doi: 10.1128/jcm.00399-22
pmc: PMC9199414
doi:
Substances chimiques
RNA
63231-63-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0039922Subventions
Organisme : NIAID NIH HHS
ID : R03 AI140183
Pays : United States
Organisme : Division of Intramural Research, National Institute of Allergy and Infectious Diseases (DIR, NIAID)
ID : AI140183-01
Références
Sex Transm Dis. 2018 Mar;45(3):177-182
pubmed: 29420445
Infect Dis Obstet Gynecol. 2016;2016:5758387
pubmed: 27366021
Clin Infect Dis. 2021 Sep 7;73(5):824-831
pubmed: 33606009
Lancet. 2019 Jun 22;393(10190):2511-2520
pubmed: 31056291
Sex Transm Dis. 2014 Oct;41(10):595-600
pubmed: 25211254
MMWR Recomm Rep. 2021 Jul 23;70(4):1-187
pubmed: 34292926
Sex Transm Dis. 2019 Nov;46(11):743-747
pubmed: 31517767
Clin Infect Dis. 2021 Nov 2;73(9):e3196-e3200
pubmed: 32766821
Sex Transm Infect. 2017 Nov;93(7):467-471
pubmed: 28822976
Clin Infect Dis. 2020 Mar 17;70(7):1495-1500
pubmed: 31538646
Lancet Infect Dis. 2019 Oct;19(10):e360-e366
pubmed: 31324517
Clin Infect Dis. 2021 Aug 16;73(4):583-585
pubmed: 33508084
MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1911-1916
pubmed: 33332296
Sex Transm Dis. 2010 May;37(5):343-4
pubmed: 20393382
J Mol Diagn. 2006 Feb;8(1):3-15
pubmed: 16436629
Sex Transm Dis. 2017 Oct;44(10):586-592
pubmed: 28876289
Clin Infect Dis. 2016 Jun 1;62(11):1348-1355
pubmed: 26962074
Am J Clin Pathol. 2014 Mar;141(3):397-403
pubmed: 24515768
Sex Transm Dis. 2021 Dec 1;48(12S Suppl 2):S151-S156
pubmed: 34433797
Sex Transm Dis. 1995 Jan-Feb;22(1):39-47
pubmed: 7709324
Clin Infect Dis. 2021 Aug 16;73(4):575-582
pubmed: 33513222